Multiple Sclerosis may gain more treatment options for SUS

Rate our content:

There was an error making your request, please try again!
OK

Thank you!

Your evaluation is essential for us to continue improving the Pebmed Portal

OK

Multiple Sclerosis is a rare disease(4), with an inflammatory, neurological and degenerative condition(5), being one of the main causes of disability in young adults(3), with symptoms such as fatigue, depression, joint pain, changes in emotions, in balance, motor coordination, speech and swallowing, in addition to compromising movements, vision and cognition – which can seriously impair the quality of life of patients with the disease.(6-8). Scientific studies have shown that the earlier MS is diagnosed and treated, the better the prognosis and, consequently, the better quality and perspective of life for the person with the disease.(9-14) Therefore, for health systems, a a greater range of treatments can minimize the progression of the disease, directly impacting the use of health resources(1)5.

In order to support the decision-making process on the incorporation of more treatments for Multiple Sclerosis (MS) in the Unified Health System (SUS), the National Commission for the Incorporation of Technologies in the SUS – Conitec opened the Public Consultation (CP) No. 12 to hear the opinion of civil society on the inclusion of therapy for the treatment of patients with multiple sclerosis. The participation of specialists, patients and the general population until 04/25/2022 will contribute to the decision of the organ. Watch the video below and learn how to contribute to CP.

Author:

Novartis is reimagining medicine to improve and extend people’s lives. As a world leader in medicines, we use innovative scientific and digital technologies to create transformative treatments in areas of great medical need. In our search for new drugs, we are consistently ranked among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people worldwide and we are finding innovative ways to expand access to our latest treatments. Around 125,000 people of over 140 nationalities work at Novartis worldwide. Learn more at http://www.novartis.com.br

See more benefits of being a user of the PEBMED Portal:

See more benefits of being a user
from the PEBMED Portal:

7 days free with Whitebook

Application made for you, doctor, designed to bring security and objectivity to your clinical decision.

Free access to Nursebook

Access fundamental information for your daily life such as anamnesis, semiology.

Free Forum access

Space for the exchange of experiences and constructive comments on topics related to Medicine and Health.

unlimited access

Get access to news, studies, updates and more content written and reviewed by experts

Test your knowledge

Answer our quizzes and study in a simple and fun way

custom content

Receive studies, updates, new behaviors and other content segmented by specialties by email

1 Cassiano DP, Esteves DDC, Cavalcanti IC, Rossi M De, Sena MS, Souza RDO. Brazilian Journal of Health Review. 2020;(June 2019):19850–61. 2 Id GK, Teich V, Cavalcanti M, Canzonieri AM. Burden and cost of multiple sclerosis in Brazil. 2019;1–12. 3 Who Gets MS? | National Multiple Sclerosis Society. Available at https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS. Accessed in March 2022. 4 from Gama Pereira ABCN, Sampaio Lacativa MC, from Costa Pereira FFC, Papais Alvarenga RM. Prevalence of multiple sclerosis in Brazil: A systematic review. Mult Scler Relat Disord [Internet]. 2015 Nov;4(6):572–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211034815001212 5 Bienes, Gabriel; Oliveira, Enedina Maria Lobato; Bichuetti, Denis Bernardi. Multiple sclerosis / Multiple sclerosis LILACS-Express | LILACS | ID: biblio-2482. Available at: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-2482 6 MS Symptoms | National Multiple Sclerosis Society. Available at https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Accessed March 2022. 7 Ziemssen T, Derfuss T, by Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol.2016;263(6):1053-1065. 8 Giovannoni G. Can we afford not to prevent MS-related disability? Mult Scler. 2017 Jul;23(8):1048-1049 9 Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedström AK, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler J [Internet]. 2017 Aug 17;23(9):1233–40. Available from: http://journals.sagepub.com/doi/10.1177/1352458516675039 10 Stankiewicz JM, Weiner HL. An argument for broad use of high and effective treatments in early multiple sclerosis. 2020;0. 11 Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D, et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemp Clin Trials [Internet]. 2020 Aug;95:106009. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1551714420300872 12 Traditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial [Internet]. [cited 2021 Jul 29]. Available from:https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/project_restore/project-restore-newsletter/traditional-versus-early-aggressive-therapy-for-multiple-sclerosis-treat-ms-trial 13 Simpson A, Mowry EM, Newsome SD. Early Aggressive Treatment Approaches for Multiple Sclerosis. 2021;1–21. 14 Zwibel HL, Smrtka J. Improving Quality of Life in Multiple Sclerosis: An Unmet Need. 2011;139–45. 15 Nicholas J, Zhou H, Deshpande C. Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis. Adv Ther [Internet]. 2021;38(1):758–71. Available from: https://doi.org/10.1007/s12325-020-01570-0